GIP and GLP-1 receptor co-agonist
Ct388 sc
CT388_SC
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 3.09 (0.19 to 108) | 0.34 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.50 (0.01 to 35.58) | 0.73 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.16 (0.38 to 19.74) | 0.60 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 8.33 (0.83 to 211) | 0.36 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.76 (0.28 to 20.02) | 0.51 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.20 (0.02 to 1.88) | 0.92 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.48 (0.01 to 39.54) | 0.70 |